
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : INF108
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Infinant Health Announces Submission of Orphan Drug Designation Application
Details : Infinant Health's patented drug candidate is a Bifidobacterium longum subspecies infantis strain, INF108, being developed for the prevention of necrotizing enterocolitis in pre-term infants.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2024
Lead Product(s) : INF108
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
